FDHT PET and Bicalutamide in Metastatic Breast Cancer

Sponsor

University Medical Center Groningen (Other)

Overall Status

Completed

CT.gov ID

NCT02697032

Collaborator

(none)

Enrollment

Location

Arm

45.8

Actual Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Rationale: The purpose is to evaluate whether non-invasive in vivo imaging of androgen receptor (AR) presence in metastatic breast cancer patients by means of 18F-fluoro-dihydrotestosterone positron emission tomography (FDHT-PET) can be used to predict (early) treatment response to, and optimal dosing of, the anti androgen bicalutamide. The ultimate goal is to contribute to optimal selection of breast cancer patients for anti androgen treatment. Objective: Feasibility to detect a diffrence in uptake on 18F-FDHT scan after 6 weeks of treatment with bicalutamide in metastatic breast cancer patients. Secondary Objectives: to describe whether changes in 18F-FDHT tracer uptake after six weeks associates with response to bicalutamide, to describe whether changes in AR availability are different for breast cancer subgroups during treatment with bicalutamide and to describe whether 18F-FDHT tracer uptake is influenced by the amount of AR tumor expression. Study design: This is a single arm, one stage feasibility study, which will be executed in the University Medical Center Groningen, The Netherlands. The primary endpoint of the study is to evaluate the difference in 18F-FDHT uptake in tumor lesions after 6 weeks of bicalutamide treatment in patients with AR-positive metastatic breast cancer. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered. Study population: The investigators will include 20 postmenopausal metastatic breast cancer patients with an AR positive, HER2 negative tumor. Patients should be restaged clinically with bone scintigraphy and CT scan within a 6 week timeframe of the PET examinations. Intervention: All patients will receive a baseline FDHT-PET scan and start with bicalutamide treatment 150mg daily. During follow-up patients will receive one FDHT-PET scan after 6 weeks. Treatment with bicalutamide will continue until progression or unacceptable toxicity is encountered. Main study endpoint: The percent difference in 18F-FDHT uptake in tumor lesions after 6 weeks of monotherapy bicalutamide. A minimum decrease of 20% in 18F-FDHT uptake after 6 weeks compared to baseline uptake with an α of 0.05 and a power of 80%, is considered clinical significant.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Drug: Bicalutamide Procedure: FDHT PET	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

22 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide

Actual Study Start Date :

Feb 1, 2016

Actual Primary Completion Date :

Nov 25, 2019

Actual Study Completion Date :

Nov 25, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Patients At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.	Drug: Bicalutamide 150mg Other Names: casodex Procedure: FDHT PET PET scan Other Names: 18F-FDHT PET

Arm

Intervention/Treatment

Experimental: Patients

At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.

Drug: Bicalutamide

150mg

Other Names:

casodex

Procedure: FDHT PET

PET scan

Other Names:

18F-FDHT PET

Outcome Measures

Primary Outcome Measures

quantify residual AR binding sites in metastatic breast cancer [6 weeks]
To quantify residual AR binding sites in metastatic breast cancer after 6 weeks of treatment with bicalutamide.

Secondary Outcome Measures

determine whether changes in 18F-FDHT uptake [6 weeks]
To determine whether changes in 18F-FDHT uptake after 6 weeks associates with response to bicalutamide.
Influence amount of AR tumor expression [6 weeks]
To determine whether 18F-FDHT tracer uptake is influenced by the amount of AR tumor expression.
Difference in changes in AR availability [6 weeks]
To determine whether changes in AR availability are different for breast cancer subgroups during treatment with bicalutamide

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

A history of histological proven AR-positive (i.e. >10% staining), HER2-negative metastatic breast cancer (preferably assessment on fresh metastasis biopsy, alternatively archival metastasis biopsy)
Tumor progression after at least one line of systemic treatment
Measurable disease according to RECIST 1.1; or evaluable disease
Age ≥ 18 years
Postmenopausal status defined as one of the following:

Age ≥60 years
Previous bilateral oophorectomy
Age <60 years and amenorrhea for >12 months in the absence of interfering hormonal therapies (such as LH-RH agonists and ER-antagonists
Age <60 years using ER antagonists should have amenorrhea for >12 months and FSH

24U/L and LH>14U/L

Adequate hematological, renal and liver function as follows:

Absolute neutrophil count > 1.5 x 109/L
Platelet count >100 x 109/L
White blood cell count >3 x 109/L
AST and ALT <3.0 x upper limit of normal (ULN)
Alkaline phosphatase <2.5 x ULN
Creatinine clearance >50mL/min
Lipase/amylase <1/5 x ULN
Protrombin time, partial tromboplastin time and INR <1.5 x ULN

Written informed consent

Exclusion Criteria:

Unable to comply with the protocol
Evidence of central nervous metastases
Presence of life-threatening visceral metastases
Corrected QT interval (QTc) >500millliseconds at screening
Recent history of cardiac disease, including myocardial infarction, unstable angina pectoris or uncontrolled arrhythmia within 6 months prior to screening; or evidence of severe congestive heart failure with New York Heart Association severity classification > class I.
Recent history of trombo-embolic events within 6 months prior to screening
Hepatic impairment (Child-Pugh Class B or C)
Severe concurrent disease, infection, co morbid condition that, in the judgment of the investigator would make the patient inappropriate for enrollment
The concomitant use of strong CYP3A4 inhibitors (see table 1)
Previous anti-androgen treatment
Concurrent use of ER-directed anti hormonal therapies
Radiotherapy or major surgery within 4 weeks before baseline PET scanning